Northwestern Mutual Wealth Management Co. Purchases 56,582 Shares of Hims & Hers Health, Inc. $HIMS

Posted by Stanley Muller on May 28th, 2026

Northwestern Mutual Wealth Management Co. boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 10,635.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,114 shares of the company’s stock after buying an additional 56,582 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Hims & Hers Health were worth $1,854,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pathway Capital Management LP bought a new stake in Hims & Hers Health in the 3rd quarter valued at about $6,766,000. Farallon Capital Management LLC increased its holdings in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. BIT Capital GmbH increased its holdings in Hims & Hers Health by 73.8% during the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after purchasing an additional 938,728 shares in the last quarter. State of Michigan Retirement System increased its holdings in Hims & Hers Health by 49.2% during the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after purchasing an additional 678,600 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in Hims & Hers Health by 25.6% during the 4th quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock worth $12,064,000 after purchasing an additional 75,679 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, COO Michael Chi sold 97,289 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $2,402,065.41. Following the transaction, the chief operating officer owned 407,282 shares in the company, valued at approximately $10,055,792.58. This represents a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 9,463 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the transaction, the insider owned 299,368 shares in the company, valued at approximately $8,981,040. The trade was a 3.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 212,807 shares of company stock valued at $5,473,644 in the last quarter. 11.76% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

HIMS stock opened at $25.24 on Thursday. The firm has a market cap of $5.84 billion, a PE ratio of -280.41, a P/E/G ratio of 46.28 and a beta of 2.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The business has a 50 day moving average of $24.02 and a 200-day moving average of $27.59. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same period in the prior year, the company earned $0.20 earnings per share. The business’s revenue was up 3.8% on a year-over-year basis. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Director David B. Wells bought 48,400 shares for about $1.17 million at $24.23 per share, increasing his stake by 27.5%. Investors often view insider buying as a bullish signal that management believes the stock is undervalued. Hims & Hers Stock Spikes — Insider Sends Strong Signal With $1 Million Buy
Positive Sentiment: Another report highlighted the same insider purchase and noted Hims & Hers gained about 5% intraday on the news, reinforcing that the stock’s move is being driven by bullish insider sentiment. Hims & Hers Gains 5% on Insider Buying
Neutral Sentiment: Analyst commentary comparing Hims & Hers with Tempus AI may keep attention on HIMS as an AI-healthcare growth story, but it does not appear to be a direct catalyst for the stock move today. HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
Negative Sentiment: Bank of America lowered its price target on HIMS to $25 from $28 and warned that the company may need a significant ramp in GLP-1 subscriber growth to meet 2026 guidance, which adds a cautionary note for investors. Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Canaccord Genuity Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday, May 12th. Weiss Ratings lowered Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Evercore set a $24.00 price objective on Hims & Hers Health in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Finally, Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $28.70.

Check Out Our Latest Stock Report on HIMS

About Hims & Hers Health

(Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.